Progyny (PGNY) Canaccord Genuity's 46th Annual Growth Conference summary
Event summary combining transcript, slides, and related documents.
Canaccord Genuity's 46th Annual Growth Conference summary
11 Aug, 2026Business performance and seasonality
Q2 results showed pronounced summer seasonality in member utilization, similar to 2022, but engagement is expected to rebound in September and remain strong through year-end.
Seasonality is attributed to members delaying treatments for personal reasons during summer, with activity levels returning to normal post-summer.
Guidance and expectations for the remainder of the year are based on current visibility and predictive models, with confidence in meeting targets.
Sales pipeline, renewals, and expansion
Early renewal commitments have de-risked next year's renewal rates, with a significant portion of clients renewing ahead of schedule.
New sales activity is ahead of last year, with strong early commitments and a healthy pipeline, supporting the goal of adding 1 million new members.
Upselling and benefit expansions are common, with 20%-30% of clients typically adding new features; no indications of benefit reductions.
Market dynamics and client diversification
Early commitments this year are more weighted toward competitive takeaways (brownfield) rather than new market entries (greenfield), driven by cost management needs.
Client base has diversified from technology to over 45 industries, including government and healthcare, with ongoing penetration across sectors.
Infertility prevalence and demand for benefits are consistent across company sizes and industries, supporting broad market relevance.
Latest events from Progyny
- Record Q2 2026 revenue, profit, and margin growth, with strong outlook and share repurchases.PGNY
Q2 2026 - Record revenue, strong retention, and all proposals approved; poised for growth in 2026.PGNY
AGM 2026 - Robust demand, high retention, and product expansion position the business for sustained growth.PGNY
Bank of America Global Healthcare Conference 2026 - Q1 revenue up 12.2% (ex-large client), net income up 61%, and 8.8M shares repurchased.PGNY
Q1 2026 - Proxy covers director elections, auditor ratification, pay reforms, and governance changes.PGNY
Proxy filing - Votes will address director elections, auditor ratification, and governance amendments.PGNY
Proxy filing - Key votes include director elections, auditor ratification, and reducing supermajority voting thresholds.PGNY
Proxy filing - Aiming for $2.4B+ revenue and $500M+ Adjusted EBITDA by 2028, leveraging new products and expansion.PGNY
Investor Day 2024 - Record Q1 revenue, double-digit EBITDA growth, and raised guidance amid strong demand.PGNY
Q1 2025